Jin-Ji Yang

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 404 citations

Chemotherapy Versus Placebo, Medicine, First-line Gefitinib +9

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer

Yi‐Long Wu, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2018 · 321 citations · Full text

Pathology, Phase Ii Study, Oncology +16

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana et al. · The Lancet Respiratory Medicine · 2019 · 268 citations

Medicine, Randomised Phase 3, Immunology +9

Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma

Chao Zhang, Jianjun Zhang, Fang-Ping Xu et al. · Journal of Thoracic Oncology · 2019 · 221 citations · Full text